Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 6Fallopian Tube Neoplasms 6Neoplasms 5Neoplasm Metastasis 5Carcinoma 4Gastrointestinal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Kidney Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1Advanced Hepatocellular Carcinoma 1

Interventions

Sunitinib 4avelumab 2Axitinib 2trifluridine tipiracil drug combination 1trebananib 1palbociclib 1cabozantinib 1atezolizumab 1VMBP protocol 1Plasma Exchange 1Pharmaceutical Preparations 1Paclitaxel 1Nivolumab 1Cystoscopy 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Diseases × trebananib × Clear all
NCT01331941 2017-11-06

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Amgen

Phase 1 Completed
35 enrolled
Genitourinary

Kidney Diseases, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡